November 2, 2026: HHS tells compounders it will not enforce peptide regulations

Overview of the Regulatory Action

According to a report dated November 2, 2026, and flagged by the industry watchdog group Partnership for Safe Medicines, the U.S. Department of Health and Human Services (HHS) has communicated to pharmaceutical compounders that it does not intend to enforce certain federal restrictions on compounded peptide products. The brief dispatch, circulated via Google News aggregation, signals what appears to be a significant—if informally announced—shift in federal posture toward a category of drugs that has been the subject of years of regulatory tension between FDA, state boards of pharmacy, and the compounding industry.

It should be noted at the outset that the underlying source material available for this analysis consists of a headline and brief summary rather than a full text of an HHS directive, guidance document, or Federal Register notice. As such, this analysis proceeds from what can reasonably be inferred from the announcement and from the well-documented regulatory history of peptide compounding, while flagging areas where additional primary-source confirmation is needed before compounders or patients should alter their compliance posture.

Legal Framework and Authority

Compounded drugs occupy a distinct space within the Federal Food, Drug, and Cosmetic Act (FDCA). Traditional compounding pharmacies operate under Section 503A, which exempts qualifying compounded preparations from FDA's new drug approval, labeling, and current good manufacturing practice (cGMP) requirements, provided compounding is done pursuant to a valid patient-specific prescription and uses bulk drug substances that appear on FDA's 503A Bulk Drug Substances list or meet other statutory criteria. Larger-scale "outsourcing facilities" operate under Section 503B, added by the Drug Quality and Security Act of 2013, which permits office-use compounding without patient-specific prescriptions but imposes cGMP obligations and requires bulk substances to appear on the 503B Bulks List or be components of an FDA-approved drug.

Peptides have occupied an especially contentious position within this framework. Many popular compounded peptides—including BPC-157, thymosin beta-4, various growth-hormone-releasing peptides, and GLP-1 receptor agonist variants—have never been formally added to either bulks list, and in several instances FDA's Pharmacy Compounding Advisory Committee (PCAC) has recommended that specific peptides be placed in "Category 1" (substances with significant safety concerns that should not be compounded) rather than "Category 2" (candidates for further evaluation). FDA proposed nominations addressing several of these substances in 2023 and 2024, generating substantial pushback from compounding pharmacy trade associations, who argued that patient access to otherwise unavailable formulations would be harmed.

Enforcement discretion of the kind reportedly communicated by HHS does not alter the underlying statutory text of the FDCA, nor does it formally reclassify any peptide's bulks-list status. Rather, non-enforcement statements function as policy signals about agency prosecutorial and inspectional priorities—similar in legal character to FDA's historical use of guidance documents and "intent to exercise enforcement discretion" language seen in contexts such as the agency's phased approach to the Drug Supply Chain Security Act and its historical tolerance of certain office-use compounding during drug shortages (notably semaglutide and tirzepatide shortages in 2022–2024 under Section 506E/506C of the FDCA).

Industry Implications

For 503A and 503B compounders, a credible non-enforcement signal on peptides would materially reduce near-term legal exposure for continuing to formulate and dispense products such as BPC-157, various melanotan analogs, and GLP-1 peptide variants that have drawn FDA warning letters in prior enforcement cycles. Compounding pharmacy associations, including the Alliance for Pharmacy Compounding (APC), have long argued that rigid bulks-list timelines fail to account for clinical demand and patient access, particularly for conditions where FDA-approved alternatives are unavailable, back-ordered, or prohibitively priced.

Conversely, groups such as the Partnership for Safe Medicines—which has historically emphasized patient-safety risks associated with unapproved and under-tested compounded products—are likely to view any relaxation of enforcement as increasing exposure to adulterated, mislabeled, or contaminated peptide products entering the market without the safety and efficacy review that accompanies the New Drug Application (NDA) pathway. This tension mirrors earlier controversies surrounding compounded semaglutide, where FDA ultimately removed the drug from its shortage list in 2024 and subsequently pursued enforcement actions against compounders continuing to produce copies after the shortage was declared resolved.

Manufacturers holding approved peptide therapeutics (e.g., GLP-1 agonists, growth hormone analogs) may also view non-enforcement as a competitive threat, given that compounded versions are typically priced well below branded equivalents and are not subject to the same marketing, adverse-event reporting, or REMS obligations.

Compliance Considerations

Compounders should treat any reported non-enforcement position as, at most, a temporary and reversible exercise of agency discretion rather than a safe harbor with legal permanence. Key compliance considerations include:

• Non-enforcement discretion can be withdrawn at any time, particularly following a change in HHS or FDA leadership, an adverse event cluster, or congressional pressure.
• State boards of pharmacy retain independent authority to regulate compounding practice and may not adopt the same enforcement posture as HHS, creating a patchwork compliance landscape.
• Section 503A and 503B cGMP, labeling, and adverse-event reporting obligations are statutory, not merely discretionary, and are unlikely to be waived wholesale absent formal rulemaking.
• Compounders should maintain documentation demonstrating patient-specific prescribing (for 503A) and sourcing from FDA-registered, quality-controlled bulk suppliers, regardless of enforcement posture, to mitigate future liability.

Looking Ahead

Several developments warrant close monitoring. First, whether HHS or FDA issues a formal guidance document, Federal Register notice, or PCAC meeting outcome that memorializes this enforcement posture in writing—verbal or informal communications carry less durable legal weight. Second, whether this action is connected to broader deregulatory initiatives reportedly under consideration within HHS regarding compounding oversight generally. Third, how state pharmacy boards, manufacturers of FDA-approved peptide drugs, and patient-safety organizations respond, including potential litigation or citizen petitions challenging the discretion as arbitrary and capricious under the Administrative Procedure Act if adverse events occur.

Given the limited detail available in initial reporting, stakeholders should consult primary HHS and FDA communications directly and monitor forthcoming Federal Register notices before making material business or compliance decisions. This analysis will require updating as the underlying HHS communication, its scope, and its legal basis become more fully documented.